Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Sarcoma genetics and epigenetics


Gene fusions

Sarcomas are often characterized by the presence of oncogenic gene fusions resulting from chromosomal translocations. By generating chimeric proteins that are not present in normal cells, they are rational drug targets. Still, how many of these genetic alterations drive tumorigenesis in sarcomas remains unclear. A recurrent theme in sarcoma biology, is the implication of genes encoding chromatin-modifying activities and transcription factors. We use a diverse set of assays to understand how these oncogenic alterations deregulate normal gene expression programs leading to cancer.

Model sarcoma genetic alterations in vivo

Sarcomas are an extremely heterogeneous group of tumors that can arise in a multitude of tissues and linages but their cells of origin remain elusive. More flexible and versatile models are in need to rapidly assess the impact of different genetic alterations in vivo. We established a somatic, fast and versatile, yet genetically controlled in vivo mouse modeling platform for soft-tissue sarcomas (EPO-GEMM/electroporation-based genetically-engineered mouse models). The method is based on a mix of transposon plasmids for oncogene delivery, and CRISPR/Cas9 plasmids expressing small guide RNAs (sgRNAs) directed against tumor suppressor genes, delivered by muscle electroporation. We are taking advantage of this flexible models to optimize immunotherapies in sarcoma and understand mechanisms of tumor maintenance by gene fusions in an immunocompetent background.

to top
powered by webEdition CMS